Table 1.

Clinical and immunological profile of the studied patients

Sex	Age, years	Disease duration, years	Score	CD39+/Treg (%)	CD73+/Treg (%)
Chronic plaque psoriasis vulgaris (PV, n = 10)
M	36	9	22.0	47.7	11.3
M	32	8	36.2	52.1	7.5
F	33	7	30.2	69.5	4.7
M	43	5	20.6	64.1	6
F	28	9	23.4	18.7	8.9
F	30	12	35.7	22.3	3.6
M	33	5	42.1	45.3	5.9
F	45	18	20.0	68.5	8.2
M	46	9	18.5	30.4	7.5
M	25	10	23.5	34	6.3
Mean ± SD	35.1 ± 4	9.2 ± 2		45.3 ± 10.7	7.0 ± 1.3
Erythrodermic psoriasis (PE, n = 10)
M	30	10	–	73.7	7.4
F	39	12	–	68.1	9.0
F	62	20	–	84.5	12.7
F	36	9	–	28.1	14.5
M	43	17	–	20.5	13.3
M	59	20	–	92.7	10.2
F	45	10	–	96.4	14.5
M	38	8	–	5.4	14.3
M	39	11	–	59.3	15.2
F	49	18	–	65.1	10.9
Mean ± SD	44 ± 5.8	13.5 ± 2.7	–	59.4 ± 18.1	12.2 ± 1.5
Pustular psoriasis (PP, n = 10)
F	55	8	4	62.2	11.0
F	39	10	5	27.1	10.7
M	48	7	3	21.8	14.5
F	39	13	4	53.0	12.1
F	40	15	4	17.7	10.0
F	47	10	6	18.9	14.6
M	37	7	5	31.2	15.2
M	55	11	5	10.4	11.1
F	32	12	3	25.4	13.8
F	50	9	5	35.2	11.8
Mean ± SD	44.2 ± 4.6	10.2 ± 1.5	4.4 ± 0.6	30.3 ± 9.3	12.5 ± 1.1
Controls (n = 10)
Mean ± SD	38			58.4 ± 14	13.2 ± 3.5